[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Jonathan Cheng [@JChengWSJ](/creator/twitter/JChengWSJ) on x 85.9K followers Created: 2025-07-02 01:53:10 UTC “Ten years ago, what we saw coming out of China were more follow-on, similar drugs, less differentiation. What we are seeing today is fundamentally different: first-in-class, best-in-class,” Gilead Sciences’ CFO, Andrew Dickinson, said in January. XXXXX engagements  **Related Topics** [drugs](/topic/drugs) [china](/topic/china) [gilead sciences](/topic/gilead-sciences) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/JChengWSJ/status/1940227213829562661)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Jonathan Cheng @JChengWSJ on x 85.9K followers
Created: 2025-07-02 01:53:10 UTC
“Ten years ago, what we saw coming out of China were more follow-on, similar drugs, less differentiation. What we are seeing today is fundamentally different: first-in-class, best-in-class,” Gilead Sciences’ CFO, Andrew Dickinson, said in January.
XXXXX engagements
Related Topics drugs china gilead sciences stocks healthcare
/post/tweet::1940227213829562661